Searched for
SHILPA MEDICARE FDA
Stocks in news: Patanjali Foods, ITC Hotels, Tata Power, SBI, HUL, Balu ForgeMarkets closed slightly higher after a narrow trading range, with several companies like JSW Energy and ITC Hotels set to announce Q4 resul...- Dr Reddy’s shares in focus after recall of mislabelled Levetiracetam injection in USThe potential risks include hypersensitivity reactions, liver injury, hematological toxicity, drowsiness, dizziness, respiratory depression...
- Stocks in news: Dr Reddy’s, Shilpa Medicare, Voltas, TCS, Tata MotorsDomestic markets closed slightly lower last week amid mixed global cues. Shares of Dr Reddy’s, Shilpa Medicare, and Tata Motors will be in ...
- Stocks in news: Gensol Engineering, HCL Tech, Tata Power, NMDC, IndusInd BankTata Power's arm Tata Power Renewable Energy has signed a memorandum of understanding (MoU) with the government of Andhra Pradesh to collab...
- Stocks in news: Axis Bank, Mankind Pharma, Bank of Baroda, Laurus Labs, WiproMauritius-based Beige Ltd has sold partial stake in Mankind Pharma through bulk deals on Tuesday. The investors have sold about 1.44 crore ...
- Indian shares set to open higher ahead of March quarter earningsThe Nifty 50 has risen nearly 4% over the past six sessions. Corporate earnings, scheduled from Tuesday, will be the near-term trigger for ...
- USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant"This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceutica...
- Shilpa Medicare shares hit lower circuit after USFDA observations for Telangana unitThe US Food and Drug Administration (USFDA) issued form 483 with 15 observations to the company’s Jadcherla Unit
- Pharma sector with improved health a big draw for investorsBSE’s Healthcare index has jumped by 4 per cent in the last five trading sessions.
- Shilpa Medicare surges 11% on getting EIR from USFDA for Raichur unitsUSFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection.
- 2 wealth creation ideas for next 3 years: Rajesh Agarwal, AUM CapitalAround 5% of the total market share of highway tyres is being served by Balkrishna Industries.
- RBL and Shilpa Medicare can be great picks for medium term: Rajesh AgarwalAt 2.5 times price to book value FY18, RBL appears attractive and we recommend this for a target of Rs 390 in next 6-9 months, says the HoR...
- Shilpa Medicare on cusp on transition, hits 52-wk highThe stock hit a 52-week high of `700 on Wednesday after the company announced that it has received FDA nod for its generic cancer treatment...
- Shilpa Medicare on the cusp of transitionThe company has potential to throw many positive surprises on back of pipeline of work that it has done in past few years, according to ana...
- Huge opportunities, but also regulatory risks lie ahead for midcap pharma companies; prefer IPCA Labs: Prakash DiwanDiwan believes that Ipca Labs is at the cusp of a turnaround. He likes Ranbaxy, Cipla and Dr Reddy’s Labs among the largecap names.
- Shares of mid-cap pharma companies surge as investors seek defensive betsInvestors lapped up shares of mid-cap pharma firms on Wednesday as weakness in the broader market prompted them to focus on these bets.
- Some pharma stocks run out of steam; high valuations, regulatory issues lead to selloff pressure on StreetPharma stocks have become laggards of late, given their high valuations, regulatory issues and overall slowdown in sales.
- Our consolidated topline is Rs 73 cr: Vishnukant Bhutada, MD, Shilpa MedicareIn an interaction with ET Now, Vishnukant Bhutada, Managing Director, Shilpa Medicare, analyses the company’s earnings figures & product ch...
- Shilpa Medicare gets suitability certificate for Oxaliplatin EPShilpa Medicare has received the certificate of suitability of Monographs from European Directorate for the Quality of Medicines for the ac...
- Windfall for cos eyeing US oncology marketWith anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
Load More
